Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Constantine S Mitsiades, Nicholas Mitsiades, Teru Hideshima, Paul G Richardson & Kenneth C Anderson. (2005) Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticancer Therapy 5:3, pages 465-476.
Read now
Read now
Piotr Smolewski, Zbigniew Darzynkiewicz & Tadeusz Robak. (2003) Caspase-mediated Cell Death in Hematological Malignancies: Theoretical Considerations, Methods of Assessment, and Clinical Implications. Leukemia & Lymphoma 44:7, pages 1089-1104.
Read now
Read now
S.A. Schey. (2002) Thalidomide in the Management of Multiple Myeloma. Hematology 7:5, pages 291-299.
Read now
Read now
Articles from other publishers (24)
Waleed Arafat, Tong Zhou, George E. Naoum & Donald J. Buchsbaum. (2015) Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer. Journal of the Egyptian National Cancer Institute 27:4, pages 205-215.
Crossref
Crossref
Nathan G. Dolloff. 2015.
191
226
.
Srdjan Vitovski, Andrew D. Chantry, Michelle A. Lawson & Peter I. Croucher. (2012) Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo. PLoS ONE 7:5, pages e35830.
Crossref
Crossref
Tanvi S. Jani, Jennifer DeVecchio, Tapati Mazumdar, Akwasi Agyeman & Janet A. Houghton. (2010) Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin. Journal of Biological Chemistry 285:25, pages 19162-19172.
Crossref
Crossref
Sabino Ciavarella, Annalisa Milano, Franco Dammacco & Franco Silvestris. (2010) Targeted Therapies in Cancer. BioDrugs 24:2, pages 77-88.
Crossref
Crossref
D. Schilling, R. Küfer, S. Kruck, A. Stenzl, M.A. Kuczyk & A.S. Merseburger. (2008) Somatostatin-Analoga in der Therapie des fortgeschrittenen hormonrefraktären ProstatakarzinomsSomatostatin analogs for the treatment of advanced, hormone-refractory prostate cancer. Der Urologe 47:10, pages 1334-1338.
Crossref
Crossref
Roya Khosravi-Far & Eileen WhiteRobin C. Humphreys & Wendy Halpern. 2008. Programmed Cell Death in Cancer Progression and Therapy. Programmed Cell Death in Cancer Progression and Therapy
127
158
.
Maria Gómez-Benito, Maria José Martinez-Lorenzo, Alberto Anel, Isabel Marzo & Javier Naval. (2007) Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Experimental Cell Research 313:11, pages 2378-2388.
Crossref
Crossref
R M Locklin, P I Croucher, R G G Russell & C M Edwards. (2007) Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21:4, pages 805-812.
Crossref
Crossref
T Liu, C Laurell, G Selivanova, J Lundeberg, P Nilsson & K G Wiman. (2006) Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death & Differentiation 14:3, pages 411-421.
Crossref
Crossref
Amir Harandi. (2006) Immunoplacental therapy, a potential multi-epitope cancer vaccine. Medical Hypotheses 66:6, pages 1182-1187.
Crossref
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Teru Hideshima & Kenneth C. Anderson. (2005) Novel biological therapies for the treatment of multiple myeloma. Best Practice & Research Clinical Haematology 18:4, pages 619-634.
Crossref
Crossref
Constantine S. MitsiadesNicholas MitsiadesTeru HideshimaPaul G. RichardsonKenneth C. Anderson. (2005) Proteasome inhibitors as therapeutics. Essays in Biochemistry 41, pages 205-218.
Crossref
Crossref
Chun CrowderØyvind DahleR. Eric DavisOdd S. GabrielsenStuart Rudikoff. (2005) PML mediates IFN-α–induced apoptosis in myeloma by regulating TRAIL induction. Blood 105:3, pages 1280-1287.
Crossref
Crossref
S. Bouralexis, D. M. Findlay & A. Evdokiou. (2005) Death to the bad guys: Targeting cancer via Apo2L/TRAIL. Apoptosis 10:1, pages 35-51.
Crossref
Crossref
Maurizio Zangari, Elias Anaissie, Alison Stopeck, Alyssa Morimoto, Nguyen Tan, Jeffrey Lancet, Maureen Cooper, Alison Hannah, Guillermo Garcia-Manero, Stephan Faderl, Hagop Kantarjian, Julie Cherrington, Maher Albitar & Francis J. Giles. (2004) Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma. Clinical Cancer Research 10:1, pages 88-95.
Crossref
Crossref
Izabela Młnarczuk, Paweł Mróz, Grażyna Hoser, Dominika Nowis, Łukasz P. Biały, Halina Ziemba, Tomasz Grzela, Wojciech Feleszko, Jacek Malejczyk, Cezary Wójcik, Marek Jakóbisiak & Jakub Gołąb. (2004) AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leukemia Research 28:1, pages 53-61.
Crossref
Crossref
Anas YounesMarshall E. Kadin. (2003) Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy. Journal of Clinical Oncology 21:18, pages 3526-3534.
Crossref
Crossref
S.A. Schey. (2003) Myeloma. European Journal of Cancer Supplements 1:1, pages 35-41.
Crossref
Crossref
Bei Zheng, Paolo Fiumara, Yang V. Li, Georgios Georgakis, Virginia Snell, Mamoun Younes, Jean Nicolas Vauthey, Antonino Carbone & Anas Younes. (2003) MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102:3, pages 1019-1027.
Crossref
Crossref
Diely Pichardo, Seema Singhal, Jayesh Mehta & Steven Rosen. (2003) Recent Developments and Future Directions in the Treatment of Multiple Myeloma. Cancer Biotherapy and Radiopharmaceuticals 18:4, pages 497-511.
Crossref
Crossref
Francis J. Giles. (2002) New drugs in acute myeloid leukemia. Current Oncology Reports 4:5, pages 369-374.
Crossref
Crossref
Deepak Gupta, Teru Hideshima & Kenneth C. Anderson. (2002)
N
OVEL
B
IOLOGICALLY
B
ASED
T
HERAPEUTIC
S
TRATEGIES
IN
M
YELOMA
. Reviews in Clinical and Experimental Hematology 6:3, pages 301-324.
Crossref
Crossref
William S. Dalton, P. Leif Bergsagel, W. Michael Kuehl, Kenneth C. Anderson & J. L. Harousseau. (2001) Multiple Myeloma. Hematology 2001:1, pages 157-177.
Crossref
Crossref